Business Context and Reporting Period
This Form 8-K is filed by New York Mortgage Trust, Inc. (noted as Adamas Trust, Inc. in metadata) on December 22, 2011. The report addresses a governance issue regarding the resignation of an independent director and the resulting non-compliance with Nasdaq listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status.
Material Changes
- Director Resignation: Daniel K. Osborne, an independent director and member of the Audit, Compensation, and Nominating and Corporate Governance Committees, resigned effective December 30, 2011.
- Listing Non-Compliance: Following the resignation, the Board will consist of four directors, only two of whom are independent. This violates Nasdaq Listing Rule 5605, which requires a majority of independent directors and an audit committee of at least three independent directors.
- Formal Notice: The Company notified Nasdaq on December 22, 2011, of the impending non-compliance effective December 30, 2011.
Outlook, Risks, and Management Commentary
- Cure Period: The Company has been granted a cure period to regain compliance. The deadline is the earlier of the next annual stockholders' meeting or December 30, 2012. If the annual meeting occurs before June 27, 2012, compliance must be evidenced by June 27, 2012.
- Recruitment Plan: The Nominating and Corporate Governance Committee has begun identifying a qualified independent director candidate. The Company expects to fill the vacancy in the first quarter of 2012.
- Regulatory Notification: The Company expects to receive formal notification from Nasdaq regarding the failure to satisfy continued listing rules during the first week of 2012.
Investor Verification Checklist
- Confirm the date of the next annual stockholders' meeting to determine the exact compliance deadline.
- Monitor announcements regarding the appointment of a new independent director to ensure the vacancy is filled by the first quarter of 2012.
- Watch for formal correspondence from Nasdaq regarding the delisting risk or extension of the cure period.
- Verify the composition of the Audit Committee to ensure it meets the minimum requirement of three independent directors once the new director is appointed.